Publications by authors named "Yasuto Takeuchi"

Claim this Profile
O
Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.
Takanori Ito, Shigeo Shimose, Issei Saeki, Yasuto Takeuchi, Joji Tani

J Gastroenterol Hepatol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B.
Ryu Sasaki, Shigeo Shimose, Issei Saeki, Takanori Ito, Yasuto Takeuchi

Liver Int· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study.
Takeshi Hatanaka, Shigeo Shimose, Takanori Ito, Joji Tani, Tetsu Tomonari, Yasuto Takeuchi, Mamiko Takeuchi

Hepatol Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nationwide comprehensive genomic profiling defines the genomic landscape of hepatocellular carcinoma across etiologies.
Kengo Yasugi, Yoshiyasu Kono, Koichiro Tsutsumi, Shigeru Horiguchi, Chihiro Sakaguchi, Yasuto Takeuchi

Sci Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Variables That Predict Liver-related Events in Steatotic Liver Disease Diagnosed by a Liver Biopsy.
Shinnosuke Okubo, Akinobu Takaki, Ikumi Sato, Takuya Adachi, Yasuto Takeuchi

Intern Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan.
Shigeo Shimose, Issei Saeki, Takanori Ito, Yasuto Takeuchi, Joji Tani

Hepatol Int· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel approach to evaluate the therapeutic efficacy of durvalumab and tremelimumab combination therapy in hepatocellular carcinoma.
Tetsu Tomonari, Shigeo Shimose, Issei Saeki, Joji Tani, Yuichi Honma, Mamiko Takeuchi, Yasuto Takeuchi

Hepatol Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Impact of Gastrointestinal Immune-Related Adverse Events Depends on Nutritional Status in Cancer Patients Treated with Immune Checkpoint Inhibitors.
Shoichiro Hirata, Yoshiyasu Kono, Emi Tanaka, Masahiko Sue, Yasuto Takeuchi

Cancers (Basel)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of endoscopic ultrasonography-guided radiofrequency ablation of small pancreatic neuroendocrine neoplasms: A prospective, pilot study.
Kazuyuki Matsumoto, Daisuke Uchida, Yasuto Takeuchi, Hironari Kato, Yuki Fujii

DEN Open· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor effects and immune-mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma.
Takanori Ito, Shigeo Shimose, Joji Tani, Tetsu Tomonari, Issei Saeki, Yasuto Takeuchi, Mamiko Takeuchi

Hepatol Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNA binding protein ZCCHC24 promotes tumorigenicity in triple-negative breast cancer.
Yutaro Uchida, Ryota Kurimoto, Tomoki Chiba, Takahide Matsushima, Goshi Oda, Yasuto Takeuchi

EMBO Rep· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy.
Issei Saeki, Shigeo Shimose, Tetsu Tomonari, Takanori Ito, Joji Tani, Yasuto Takeuchi, Mamiko Takeuchi

PLoS One· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic guide for immune checkpoint inhibitor-induced liver injury.
Takanori Ito, Yasuto Takeuchi, Kazuyuki Mizuno, Michitaka Imai, Yoko Yoshimaru

Hepatol Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice.
Shigeo Shimose, Issei Saeki, Tetsu Tomonari, Takanori Ito, Joji Tani, Yasuto Takeuchi, Mamiko Takeuchi

Oncol Lett· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-PD-1 Autoantibody Predicts Survival of Patients With Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab.
Yuki Sasaki, Kazuyuki Matsumoto, Akinobu Takaki, Takuya Adachi, Masahiro Takahara, Yasuto Takeuchi

Gastro Hep Adv· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to the letter: "Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab".
Tatsuya Kikuchi, Yasuto Takeuchi, Kazuhiro Nouso, Kazuya Kariyama, Kenji Kuwaki

Liver Int· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab.
Tatsuya Kikuchi, Yasuto Takeuchi, Kazuhiro Nouso, Kazuya Kariyama, Kenji Kuwaki

Liver Int· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Nutritional Status on Neutrophil-to-Lymphocyte Ratio as a Predictor of Efficacy and Adverse Events of Immune Check-Point Inhibitors.
Masahiko Sue, Yasuto Takeuchi, Shoichiro Hirata, Akinobu Takaki, Motoyuki Otsuka

Cancers (Basel)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Luciferase Reporter Assay to Detect Cellular Hypoxia In Vitro.
Masayuki Inubushi, Yasuto Takeuchi, Chika Murai, Yoshimasa Kitagawa

Methods Mol Biol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radionuclide Reporter Imaging to Visualize Tumor Hypoxia Ex Vivo and In Vivo.
Masayuki Inubushi, Yasuto Takeuchi, Yoshimasa Kitagawa

Methods Mol Biol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persisters.
Mengjiao Li, Tatsunori Nishimura, Yasuto Takeuchi, Tsunaki Hongu, Yuming Wang

J Clin Invest· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oxidative stress-related markers as prognostic factors for patients with primary sclerosing cholangitis in Japan.
Atsushi Oyama, Akinobu Takaki, Takuya Adachi, Nozomu Wada, Yasuto Takeuchi

Hepatol Int· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitochondrial one-carbon metabolic enzyme MTHFD2 facilitates mammary gland development during pregnancy.
Yuming Wang, Tsunaki Hongu, Tatsunori Nishimura, Yasuto Takeuchi, Hiroshi Takano

Biochem Biophys Res Commun· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab.
Yasuto Takeuchi, Kazuhiro Nouso, Shin-Ichi Fujioka, Kazuya Kariyama, Haruhiko Kobashi

Cancer Med· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease Progression-Related Markers for Aged Non-Alcoholic Fatty Liver Disease Patients.
Kosaku Morimoto, Yasuto Takeuchi, Akinobu Takaki, Nozomu Wada, Atsushi Oyama

Acta Med Okayama· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis